Medindia LOGIN REGISTER
Medindia
Advertisement

DiagnoCure receives approval from the U.S. regulatory authorities and launches its Previstage(TM) GCC Colorectal Cancer Staging Test

Tuesday, August 26, 2008 General News
Advertisement
QUEBEC CITY, Aug. 26 /PRNewswire-FirstCall/ - DiagnoCure OncologyLaboratories, based in West Chester, PA, a wholly-owned subsidiary ofDiagnoCure Inc., announced today that it has received the U.S. CLIAcertification required for the Company to launch its new laboratory developedPrevistage(TM) GCC Colorectal Cancer Staging Test. The sales team can nowactively promote the test, and the Company's U.S. clinical laboratory canperform it and report patient results worldwide.
Advertisement

"Receiving this regulatory certification is a major accomplishment inDiagnoCure's growth strategy, which will strengthen our leadership position inhigh-value molecular cancer diagnostics. We can now provide clinicians andpatients with a test using a technology that is 100,000 fold more sensitivethan the current method of staging. We can help answer the fundamentalquestion that every colorectal cancer patient asks after their surgery: Am Icured or has my cancer spread?", stated John Schafer, President and CEO ofDiagnoCure.
Advertisement

DiagnoCure Oncology Laboratories will promote and offer the test directlyto clinicians across the United States. Following the summer pre-launchmarketing campaign, several physicians have already expressed interest in thetest.

About Previstage(TM) GCC

Every year in North America, 174,000 people are diagnosed with colorectalcancer, and 142,000 colorectal cancer surgeries are performed. Staging apatient with colorectal cancer is crucial because it determines the patient'scourse of treatment after the surgery. Current standard of care requires thatpathologists microscopically examine a thin slice of tissue from the lymphnodes harvested during the patient's surgery to see if cancer has spread.Currently, up to 25 - 30 percent of patients with no pathologically-positivelymph nodes (stage I and II cancers) later develop recurrent disease,presumably through occult metastases that have escaped detection. Most ofthese patients do not receive additional therapies such as chemotherapy.Previstage(TM) GCC provides clinicians with significantly more accurateinformation for staging a patient with colorectal cancer that will increasetheir confidence in making critical treatment decisions.

Strong data supports the potential for the GCC test to improve the currentstaging of colorectal patients. The National Cancer Institute sponsored afive-year prospective clinical trial of GCC testing in colorectal cancerpatients. This study has been recently completed and the Company'scollaborators at Thomas Jefferson University are presenting the results atmajor medical conferences throughout the year.

The Previstage(TM) GCC Colorectal Cancer Staging Test is alaboratory-developed test and its performance characteristics have beenvalidated and determined by DiagnoCure Oncology Laboratories.

About DiagnoCure

DiagnoCure (TSX: CUR) is a life sciences company commercializinghigh-value cancer diagnostic tests and delivering laboratory services thatincrease clinician and patient confidence in making critical treatmentdecisions. DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure Inc.,recently launched the Previstage(TM) GCC Colorectal Cancer Staging Test, thefirst GCC-based molecular test for the management of colorectal cancer. TheCompany also has a strategic alliance with Gen-Probe (NASDAQ: GPRO) for thedevelopment and commercialization of a second-generation prostate cancer testusing PCA3, DiagnoCure's proprietary molecular marker. This test is alsoavailable through laboratories in the U.S. using PCA3 analyte specificreagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA(TM) PCA3 invitro assay, and in Canada. In addition to its own research, the Companyintends to acquire or in-license additional promising cancer biomarkers fromboth academic and commercial institutions. For more information, visitwww.diagnocure.com.

Forward-l
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close